9.6, 119.5 /H110065.4, and 117.4 /H110066.3 mg/dl (7.6 /H110060.6, 6.6 /H110060.3, and 6.5 /H110060.3 mmol/liter) for AC2993 0.05 /H9262g/kg, 0.1 /H9262g/kg, and 0.2 /H9262g/kg doses, respectively, compared with 187.9 /H11006 12.1 mg/dl (10.4 /H110060.7 mmol/liter) for placebo. There was a trend for fasting plasma glucose incremental AUC(0–8h ) and Cmax to decrease proportionally with in - creased AC2993 doses. Mean incremental AUC(0–8h )values were/H11002621.0 mg /H11003h per deciliter ( /H1100234.4 mmol /H11003h per liter; 0.2/H9262g/kg),/H11002574.1 mg /H11003h per deciliter ( /H1100231.9 mmol /H11003h per liter; 0.1 /H9262g/kg), and /H11002498.2 mg /H11003h per deciliter ( /H1100227.7 mmol/H11003h per liter; 0.05 /H9262g/kg), compared with /H11002206.8 mg/H11003h per deciliter ( /H1100211.5 mmol /H11003h per liter; placebo). Fasting serum insulin. The data demonstrate a dose-depen-